1092536-54-3

Basic information

• Product Name: Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]-
• Synonyms: Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]-;4-Benzyloxy-3,3-diMethylbut-1-yne;(((2,2-diMethylbut-3-yn-1-yl)oxy)Methyl)benzene;EOS-60787
• CAS NO: 1092536-54-3
• Molecular Formula: C₁₃H₁₆O
• Molecular Weight: 188.26554
• Mol File: 1092536-54-3.mol

Chemical Properties

• Boiling Point: 255.6±23.0 °C(Predicted)
• Appearance: /
• Density: 0.965±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]-(1092536-54-3)
• EPA Substance Registry System: Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]-(1092536-54-3)

Safety Data

• Hazardous Substances Data: 1092536-54-3(Hazardous Substances Data)

Usage

Uses

Used in Chemical Production:
Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]is used as a solvent for various chemical processes, facilitating reactions and improving the efficiency of production.
Used in Pharmaceutical Synthesis:
Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]plays a crucial role in the synthesis of pharmaceuticals, contributing to the development of new medications and therapies.
Used in Adhesives, Sealants, and Coatings Manufacturing:
Benzene, [[(2,2-diMethyl-3-butyn-1-yl)oxy]Methyl]is used as a component in the production of adhesives, sealants, and coatings, enhancing their performance and durability.
Used in the Synthesis of Other Chemicals:
It serves as a precursor in the synthesis of other chemicals, expanding its utility across different industries.

Upstream product

• 38216-93-2 3-benzyloxypivalic aldehyde 
• 60190-80-9 dimethyl (1-diazo-2-oxo-2-phenylethyl)phosphonate 
• 18387-63-8 (3-chloro-3-methylbut-1-yn-1-yl)trimethylsilane 
• 1294504-65-6 (4-(benzyloxy)-3,3-dimethylbut-1-ynyl)trimethylsilane 
• 5272-33-3 2-methyl-4-(trimethylsilyl)but-3-yn-2-ol 
• 90965-06-3 dimethyl 1-(1-diazo-2-oxopropyl)phosphonate 
• 66582-32-9 3-(benzyloxy)-2,2-dimethylpropan-1-ol 
• 126-30-7 2,2-Dimethyl-1,3-propanediol 
• 100-39-0 benzyl bromide 
• 1402615-92-2 [{(4,4-dibromo-2,2-dimethylbut-3-en-1-yl)oxy}methyl]benzene 

Downstream Products

• 1234691-52-1 1,10-bis(benzyloxy)-7-(4-methoxybenzyloxy)-2,2-dimethyldec-3-yn-5-one 
• 1152311-62-0 (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide 
• 1294504-67-8 (2R)-1-{5-amino-2-[1-(benzyloxy)-2-methylpropan-2-yl]-6-fluoro-1H-indol-1-yl}-3-(benzyloxy)propan-2-ol 
• 1294504-68-9 N-{1-[(2R)-3-(benzyloxy)-2-hydroxypropyl]-2-[1-(benzyloxy)-2-methylpropan-2-yl]-6-fluoro-1H-indol-5-yl}-1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)cyclopropane-1-carboxamide 
• 1294504-66-7 (R)-1-((4-amino-2-(4-(benzyloxy)-3,3-dimethylbut-1-yn-1-yl)-5-fluorophenyl)amino)-3-(benzyloxy)propan-2-ol 
• 1402615-50-2 [(2,2-dimethylpenta-3,4-dienyloxy)methyl]benzene 
• 1402615-67-1 methyl 2-[{2-(5-(benzyloxy)-4,4-dimethylpent-1-en-2-yl)phenyl}(methoxycarbonyl)amino]acetate 
• 1402615-98-8 C₂₂H₂₇NO₃ 

Relevant articles and documents

IMPROVED PROCESS FOR THE PREPARATION OF TEZACAFTOR INTERMEDIATE

The present invention relates to an improved process for the preparation of tezacaftor intermediate compound of formula II. More particularly, the present invention relates to an improved, commercially viable process for the preparation of tezacaftor inte

Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES

The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

CYCLOPROPANECARBOXAMIDE MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

PHARMACEUTICAL COMPOSITIONS OF (R)-1-(2,2-DIFLURORBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE AND ADMINISTRATION THEREOF

A pharmaceutical composition comprising Compound 1, (R)- 1 -(2,2- difluorobenzo[d] [ 1,3]dioxol-5-yl)-N-( 1 -(2,3-dihydroxypropyl)-6-fluoro-2-( 1 -hydroxy-2- methylpropan-2-yl)- l H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from : a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.

Solid Forms of (R)-1(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)-N-(1-(2,3-Dihydroxypropyl-6-Fluoro-2-(1-Hydroxy-2-Methylpropan-2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide

The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.

PHARMACEUTICL COMPOSITIONS FOR THE TREATMENT OF CFTR -MEDIATED DISORDERS

The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5- hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxaraide (Compound 1), solids forms, and pharmaceutical compositions thereof for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to the use of Compound ? in combination with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxoI- 5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 2), and Compound 1 in combination with (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3- dihydroxypropyl)~6~fluoro-2-( 1 -hydroxy-2-methylpropan-2-yl)- 1H-indol-5- yl)cyclopropanecarboxamide (Compound 3), for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to solid forms and formulations of Compound 2 or Compound 3 in combination with Compound 1, and pharmaceutical compositions thereof, for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Total synthesis of debromoflustramines B and e based on the intramolecular carbamoylketene-alkene [2 + 2] cycloaddition

Total synthesis of debromoflustramines B and E has been accomplished by using a platinum-catalyzed addition reaction of o-aminophenylboronic acid with the allene and an intramolecular carbamoylketene-alkene [2 + 2] cycloaddition for the construction of the basic carbon framework of the target alkaloids as the key steps.